Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in ...

Almirall has rolled out a new campaign for World Atopic Eczema Day, kicking off its “The T | Almirall has rolled out a new ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for ...

A new dose-finding study supported the potential of the carbonic anhydrase inhibitor as an alternative to CPAP machines.

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...

The True Colours of Atopic Dermatitis” campaign is aimed at raising awareness of the physical symptoms and emotional impact of this highly prevalent chronic skin condition – affecting an estimated 2% ...

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12 ...

Kerry FC were beaten on the road in Bray last eveningGoals either side of half time from Harry Groome and Guillermo Almirall ...

Bray are now unbeaten in all eight fixtures that face Kerry in the past two years – winning seven times. NEARING PLAY OFF ...

Blood biomarkers at disease onset may help predict relapse-associated worsening and progression independent of relapse ...

The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab ...